Browsing by Author "Radisavljevic, Ziv (16158297200)"
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: A single center study(2012) ;Todorovic, Milena (23010544100) ;Radisavljevic, Ziv (16158297200) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Todorovic, Vera (7006326762) ;Jovanovic, Maja Perunicic (57210906777)Mihaljevic, Biljana (6701325767)Angiogenesis in solid tumors is important for tumor growth, invasion, and metastasis. However, angiogenesis plays also an important role in hematological malignancies. We have analyzed the expression of vascular endothelial growth factor (VEGF) in the leukemic blast cells and microvessel density (MVD) in the bone marrow biopsy samples of the patients with acute lymphoblastic leukemia (ALL). Bone marrow MVD of the patients with ALL was significantly higher compared with normal controls and complete remission (P<0.001), but slightly lower than in patients with relapsed ALL (P>0.05). The bone marrow blast VEGF expression was significantly higher in newly diagnosed ALL patients, with predominant strong VEGF expression as compared with complete remission patients (who had negative or weak VEGF expression) (P<0.05), whereas initial values were slightly lower than in relapsed patients. There was a strong positive correlation between VEGF expression and MVD at presentation of ALL. Stronger expression of VEGF on blast cells indicates shorter overall survival in ALL. Furthermore, initial values of MVD had positive correlation with overall survival and leukemia-free survival (P=0.024 and P=0.017, respectively). Our data suggest that increased angiogenesis (confirmed by immunohistochemical expression of VEGF in leukemic blasts), and MVD may play an important role in the pathophysiology of ALL with prognostic implications. Thus, targeting VEGF pathway may bring the new approach for ALL treatment-using antiangiogenic drugs and tyrosine kinase inhibitors in combination with standard chemotherapy regimens. Copyright © 2012 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: A single center study(2012) ;Todorovic, Milena (23010544100) ;Radisavljevic, Ziv (16158297200) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Todorovic, Vera (7006326762) ;Jovanovic, Maja Perunicic (57210906777)Mihaljevic, Biljana (6701325767)Angiogenesis in solid tumors is important for tumor growth, invasion, and metastasis. However, angiogenesis plays also an important role in hematological malignancies. We have analyzed the expression of vascular endothelial growth factor (VEGF) in the leukemic blast cells and microvessel density (MVD) in the bone marrow biopsy samples of the patients with acute lymphoblastic leukemia (ALL). Bone marrow MVD of the patients with ALL was significantly higher compared with normal controls and complete remission (P<0.001), but slightly lower than in patients with relapsed ALL (P>0.05). The bone marrow blast VEGF expression was significantly higher in newly diagnosed ALL patients, with predominant strong VEGF expression as compared with complete remission patients (who had negative or weak VEGF expression) (P<0.05), whereas initial values were slightly lower than in relapsed patients. There was a strong positive correlation between VEGF expression and MVD at presentation of ALL. Stronger expression of VEGF on blast cells indicates shorter overall survival in ALL. Furthermore, initial values of MVD had positive correlation with overall survival and leukemia-free survival (P=0.024 and P=0.017, respectively). Our data suggest that increased angiogenesis (confirmed by immunohistochemical expression of VEGF in leukemic blasts), and MVD may play an important role in the pathophysiology of ALL with prognostic implications. Thus, targeting VEGF pathway may bring the new approach for ALL treatment-using antiangiogenic drugs and tyrosine kinase inhibitors in combination with standard chemotherapy regimens. Copyright © 2012 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: One institution study(2012) ;Todorovic, Milena (23010544100) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Stanisavljevic, Dejana (23566969700) ;Kurtovic, Nada Kraguljac (36195445000) ;Radisavljevic, Ziv (16158297200)Mihaljevic, Biljana (6701325767)The aim of this study was to evaluate the prognostic significance of international prognostic index (IPI), mantle cell lymphoma IPI (MIPI), simplified MIPI (sMIPI), and MIPI biological (MIPIb), as well as their correlation with immunophenotype, clinical characteristics, and overall survival (OS), in a selected group of 54 patients with advanced-stage mantle cell lymphoma (MCL), treated uniformly with CHOP. Seventeen patients had IV clinical stage (CS), while other 37 had leukemic phase at presentation. Diffuse type of marrow infiltration was verified in 68.5% and nodular in remainder patients. Extranodal localization (25.9%) included bowel (20.4%), pleural effusion, sinus, and palpebral infiltration. All of analyzed patients expressed typical MCL immunophenotypic profile: CD19+CD20+CD22 +CD5+Cyclin-D1+FMC7+CD79b + smIg+CD38+/-CD23-CD10-. Median OS of the whole group was 23 months, without significant differences between IV CS and leukemic phase patients. Thirty-two patients (59.3%) responded to initial treatment, 9 (16.7%) with complete and 23 (42.6%) with partial remission. Negative prognostic influence on OS had high IPI (P < 0.01), high sMIPI (P < 0.001), MIPI (P < 0.01), MIPIb (P < 0.01), extranodal localization (P < 0.01), and diffuse marrow infiltration (P < 0.01). Testing between randomly selected groups showed that patients with lower proportion of CD5+ cells (<80%) correlated with cytological blastoid variant and had shorter survival comparing with the group with higher proportion of CD5+ cells (>80%) (P < 0.01). Using univariate Cox regression, we proved that IPI, sMIPI, MIPI, and MIPIb had an independent predictive importance (P < 0.01) for OS in uniformly treated advanced MCL patients, although sMIPI prognostic significance was the highest (P < 0.001). Copyright © Springer Science+Business Media, LLC 2011. - Some of the metrics are blocked by yourconsent settings
Publication Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: One institution study(2012) ;Todorovic, Milena (23010544100) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Stanisavljevic, Dejana (23566969700) ;Kurtovic, Nada Kraguljac (36195445000) ;Radisavljevic, Ziv (16158297200)Mihaljevic, Biljana (6701325767)The aim of this study was to evaluate the prognostic significance of international prognostic index (IPI), mantle cell lymphoma IPI (MIPI), simplified MIPI (sMIPI), and MIPI biological (MIPIb), as well as their correlation with immunophenotype, clinical characteristics, and overall survival (OS), in a selected group of 54 patients with advanced-stage mantle cell lymphoma (MCL), treated uniformly with CHOP. Seventeen patients had IV clinical stage (CS), while other 37 had leukemic phase at presentation. Diffuse type of marrow infiltration was verified in 68.5% and nodular in remainder patients. Extranodal localization (25.9%) included bowel (20.4%), pleural effusion, sinus, and palpebral infiltration. All of analyzed patients expressed typical MCL immunophenotypic profile: CD19+CD20+CD22 +CD5+Cyclin-D1+FMC7+CD79b + smIg+CD38+/-CD23-CD10-. Median OS of the whole group was 23 months, without significant differences between IV CS and leukemic phase patients. Thirty-two patients (59.3%) responded to initial treatment, 9 (16.7%) with complete and 23 (42.6%) with partial remission. Negative prognostic influence on OS had high IPI (P < 0.01), high sMIPI (P < 0.001), MIPI (P < 0.01), MIPIb (P < 0.01), extranodal localization (P < 0.01), and diffuse marrow infiltration (P < 0.01). Testing between randomly selected groups showed that patients with lower proportion of CD5+ cells (<80%) correlated with cytological blastoid variant and had shorter survival comparing with the group with higher proportion of CD5+ cells (>80%) (P < 0.01). Using univariate Cox regression, we proved that IPI, sMIPI, MIPI, and MIPIb had an independent predictive importance (P < 0.01) for OS in uniformly treated advanced MCL patients, although sMIPI prognostic significance was the highest (P < 0.001). Copyright © Springer Science+Business Media, LLC 2011. - Some of the metrics are blocked by yourconsent settings
Publication Quadruple metachronous malignancy in a single patient with multiple sclerosis(2012) ;Buta, Marko (16202214500) ;Ito, Yasuhiro (35427371100) ;Radisavljevic, Ziv (16158297200) ;Milovanovic, Zorka (25228841900) ;Lavrnic, Dragana (6602473221) ;Djurisic, Igor (13411475700) ;Oruci, Merima (57189327361) ;Pupic, Gordana (6507142544)Dzodic, Radan (6602410321)Quadruple primary malignancies occur with an incidence of less than 0.1%. Only less than hundred cases have been published until today. The number of multiple malignancies reported is gradually increasing. Here, we present a female patient with a multiple sclerosis and quadruple cancers from different embryological origin. The patient had medullary thyroid carcinoma (stage III-T3, N1a, M0) and multicentric micropapillary carcinomas, two melanomatous lesions, 1.24 and 0.85 mm thick (Clark II, Breslow II) and breast cancer (T1a, N0, M0). There were no signs of disease recurrence during the 5 years including the exam performed last month. Further genomic studies and closer clinical attention are needed to clarify the relation between secondary malignancies, applied treatments and endogenous and exogenous carcinogens in the process of carcinogenesis in quadruple malignancies.
